Prothrombotic gene expression profile in vascular smooth muscle cells of human saphenous vein, but not internal mammary artery by Payeli, S K et al.
Prothrombotic Gene Expression Profile in Vascular Smooth
Muscle Cells of Human Saphenous Vein, but Not
Internal Mammary Artery
S.K. Payeli, R. Latini, C. Gebhard, A. Patrignani, U. Wagner, T.F. Lu¨scher, F.C. Tanner
Background—The resistance of internal mammary artery (IMA) toward thrombotic occlusion and accelerated atheroscle-
rosis is not well understood. This study analyzed gene expression profiles of vascular smooth muscle cells (VSMCs)
from IMA versus saphenous vein (SV).
Methods and Results—54675 probe sets were examined by Affymetrix microarrays. Thirty-one genes belonged to the
coagulation system; 2 were differentially expressed, namely tissue factor (TF) and tissue-type plasminogen activator
(tPA). TF was 3.1-fold lower in IMA than SV (P0.006), whereas tPA was 9.0-fold higher (P0.001). TF mRNA
expression was lower in IMA than SV (P0.05); tPA was higher (P0.001). TF protein expression was 4.20.5-fold
lower in IMA than SV (P0.001); tPA was 2.60.4-fold higher (P0.01). In IMA VSMC supernatant, TF protein and
activity was lower (P0.05), TFPI and tPA protein higher (P0.05 and P0.005), and clotting time of human plasma
prolonged (P0.05) as compared to SV. Migration to TF/FVIIa (109 mol/L) was 3-fold lower in IMA than SV
(P0.01); PAR-2 protein expression was similar (PNS), PAR-2 blockade without effect (PNS).
Conclusions—Among the genes of the coagulation system, TF and tPA are differentially expressed in VSMCs from IMA
versus SV. This is consistent with protection of IMA from thrombus formation and vascular remodeling. (Arterioscler
Thromb Vasc Biol. 2008;28:705-710)
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Coronary artery bypass grafting improves prognosis ofpatients with coronary artery disease.1,2 Various factors
predict graft patency, such as the surgical technique, cardiovas-
cular risk factors, and low left ventricular ejection fraction.3,4 In
addition, the type of graft has a major influence on survival;
indeed, patients with 2- or 3-vessel disease receiving an internal
mammary artery (IMA) in addition to saphenous vein (SV)
grafts exhibit higher long-term survival rates as compared to
patients treated with veins only.1,2 This difference is related to
the occurrence of SV graft disease, an adaptive response of
venous grafts leading to accelerated atherosclerosis, whereas the
IMA is strikingly resistant toward such alterations.5
SV graft disease is determined by thrombosis, intimal hyper-
plasia, and accelerated atherosclerosis.6 Thrombosis is the main
cause for vein graft occlusion within the first months after
bypass surgery, whereas the neointimal changes prevail at later
stages. Even when conducted under optimized conditions, har-
vesting of SV grafts causes extensive endothelial disruption;
indeed, more than 50% of the endothelial layer is denuded after
preparation.7 Loss of the endothelium activates coagulation via
the exposure of tissue factor (TF), a key protease activator
forming a catalytic complex with factor VIIa and thereby
initiating coagulation, on vascular smooth muscle cells
(VSMCs).8 The important role of TF in the hemostatic activation
phase early after bypass surgery is underscored by the observa-
tion that expression of TF is enhanced after coronary artery
bypass grafting irrespective of whether an on-pump or off-pump
procedure was performed.9 To limit thrombus formation, vascu-
lar cells express fibrinolytic proteins such as tissue plasminogen
activator (tPA), an enzyme mediating the conversion of plas-
minogen to plasmin. The endothelium is indeed a rich source of
tPA; loss of the endothelial layer renders fibrinolysis dependent
on tPA released from VSMCs.10
In the pathogenesis of bypass graft disease, thrombosis is
interlinked with the development of intimal hyperplasia and
accelerated atherosclerosis. VSMCs indeed migrate and pro-
liferate in response to both coagulation factors and platelet-
derived mediators.11,12 TF/FVIIa is known to stimulate mi-
gration of VSMCs; accordingly, mice lacking the cytoplasmic
domain of TF exhibit reduced neointima formation and
vascular remodeling after femoral artery injury.13 Hence,
mediators primarily regulating thrombus formation in bypass
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grafts may affect the development of later stages of bypass
graft disease as well.
VSMCs are a heterogenous cell population, and different
intrinsic properties of VSMCs from IMA versus SV seem to
represent an important factor in the pathogenesis of bypass graft
disease. VSMCs from IMA indeed exhibit lower contractility as
well as lower proliferation and migration rates compared to cells
from SV.5,12,14 To improve our understanding of this heteroge-
neity, we compared the expression profile of genes involved in
coagulation between VSMCs from IMA and SV segments
retrieved during coronary artery bypass surgery using the Af-
fymetrix microarray technology.
Materials and Methods
For the detailed Materials and Methods please see online supplement
Materials and Methods at http://atvb.ahajournals.org.
VSMCs of IMA and SV were isolated from 9 patients undergoing
coronary artery bypass grafting. VSMCs were cultured as described14
and only compared if they originated from the same patient.
RNA was isolated using TRIZOL reagent. 15 g of biotin-labeled
cRNA samples were randomly fragmented at 94°C and hybridized to
human genome U133 Plus 2.0 arrays. An Affymetrix gene chip
scanner 3000 was used to measure fluorescent intensity. Values were
always represented with respect to IMA VSMCs. Only genes
exhibiting a more than 2-fold difference in expression were included
for further analysis.
Real-time polymerase chain reaction (PCR) was applied to con-
firm microarray data as described.15 Protein expression was deter-
mined by Western blot analysis as described15; alternatively, ELISA
was used. The effect of VSMC supernatant on clotting time was
determined using a Start fibrometer after initiating coagulation by
the addition of 50 L calcium chloride. VSMC migration in response
to TF/FVIIa complex was assessed in a 48-well modified Boyden
chamber (Neuroprobe) as described.12
Results
Eight Genes Related to Blood Coagulation Are
Differentially Expressed in VSMCs
From IMA and SV
Gene expression profiles of VSMCs from IMA and SV seg-
ments obtained from 9 patients during coronary artery bypass
surgery were assessed by Affymetrix human genome U133 Plus
2.0 arrays (54675 probe sets). According to the Affymetrix
database, 247 genes are related to blood coagulation; the relative
expression levels of these genes are indicated along with the
respective probability values (n9) in the online supplement
“Gene List” at http://atvb.ahajournals.org. Among the 247
genes, 8 genes (11 probe sets) were differentially expressed in
VSMCs from IMA versus SV as defined by a more than
2-fold difference in expression level and statistical signifi-
cance (P0.05) in the online supplement Figure at
http://atvb.ahajournals.org.
Two Genes Belonging to the Coagulation System
Are Differentially Expressed in VSMCs
From IMA and SV
The 247 genes related to blood coagulation were filtered by the
Kyoto Encyclopedia of Genes and Genomes (KEGG; University
of Tokyo) pathway database. This analysis indicated 31 genes
belonging to the coagulation system (Figure 1). The gene
expression profile of these 31 genes was compared between
VSMCs from IMA and SV, which revealed 2 genes differen-
tially expressed in VSMCs from IMA versus SV as defined by
a more than 2-fold difference in expression level and statistical
significance (P0.05), namely tissue factor (TF; F3) and t-PA
(tPA; PLAT). Expression of TF was 3.1-fold lower in VSMCs
from IMA than SV (P0.006), whereas that of tPA was 9.0-fold
higher in IMA than SV (P0.001). In contrast to tPA, expres-
sion of urokinase-type plasminogen activator (uPA) was not
altered in VSMCs from SV as compared to IMA (n9; PNS).
Expression of tissue factor pathway inhibitor (TFPI), the
physiological inhibitor of TF, and plasminogen activator inhib-
itor (PAI)-1, the endogenous antagonist of tPA, was assessed as
well. Analysis of the 5 TFPI probe sets revealed very small
differences in expression between IMA and SV; the average
expression level was 1.2-fold lower in IMA as compared to SV.
This difference was not significant in 4 of the 5 probe sets (n9;
PNS), while reaching significance in 1 probe set (n9;
Figure 1. Expression of 54675 probe
sets is analyzed in vascular smooth
muscle cells from internal mammary
artery (IMA) and saphenous vein (SV) by
the human genome U133 Plus 2.0 array.
31 genes are directly involved in coagu-
lation; 2 of them are differentially
expressed: tissue factor (F3) and tissue
plasminogen activator (PLAT).
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P0.05; Figure 2A). The 3 PAI-1 probe sets exhibited minor
differences in mRNA expression between IMA and SV VSMCs;
the average expression level in IMA was 1.5-fold higher than in
SV, and this difference was significant in all the probe sets
(P0.05; Figure 2B).
Validation of Microarray Data at the mRNA
and Protein Level
TF mRNA expression was analyzed by real-time PCR and
observed to be 3.41.0-fold lower in VSMCs from IMA as
compared to SV (n4; P0.05; Figure 3A, upper panel). The
increase in TF mRNA expression after thrombin stimulation
reached 2.6-fold in IMA and 1.9-fold in SV VSMCs as com-
pared to basal level (n4; P0.01 for IMA and P0.01 for
SV). Real-time PCR also confirmed higher tPA mRNA expres-
sion in VSMCs from IMA as compared to SV (6.1-fold
difference; n4; P0.001; Figure 3B, upper panel). Stimulation
with thrombin did not affect the expression of tPA in VSMCs
from IMA or SV (n4; PNS).
Western blot analysis for TF protein expression revealed a
4.20.5-fold lower TF protein expression in VSMCs from IMA
as compared to SV (n5; P0.001; Figure 3A, middle panel).
Similarly, cellular TF activity (cytoplasmic and membrane) was
1.41.9 pmoles in IMA and 29.03.1 in SV (n5; P0.005;
Figure 3A, lower panel). The increase in TF protein expression
after thrombin stimulation was comparable in VSMCs from
IMA (1.80.4-fold; n5) and SV (2.10.7-fold; n5), and the
expression level was 5.21.6-fold lower in IMA as compared to
SV under these conditions (n5; P0.05). tPA protein levels
were 2.60.4-fold higher in the supernatant of VSMCs from
IMA as compared to SV (n3; P0.01; Figure 3B, middle
panel), reaching 20.54.8 ng/mL in IMA and 3.31.8 ng/mL in
SV (n7; P0.01; Figure 3B, lower panel). Stimulation with
thrombin did not affect tPA levels in VSMCs from IMA and SV
(n3; PNS).
Modulation of Coagulation by VSMCs
From IMA and SV
The functional relevance of the different gene expression
profile in VSMCs from IMA and SV was assessed. VSMCs
were first serum-starved for 48 hours, and after this time
period, cell supernatant was added to citrated human plasma
followed by analysis of clotting time. When supernatant from
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Figure 2. Expression profile of tissue fac-
tor (TF), t-PA (tPA), tissue factor pathway
inhibitor (TFPI), and plasminogen activator
inhibitor-1 (PAI-1) in vascular smooth
muscle cells from internal mammary
artery (IMA) and saphenous vein (SV).
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Figure 3. Validation of microarray data in vascular smooth mus-
cle cells (VSMCs) from internal mammary artery (IMA) and
saphenous vein (SV) at the mRNA level (upper panels) by real
time-PCR and protein level (middle and lower panels) by West-
ern blotting or ELISA.
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IMA was compared to SV, TF protein was lower (39.020.4
versus 95.333.1 pg/mL; n5; P0.05; Figure 4A) in an
ELISA, TF activity was lower (10.71.4 versus 18.62.7
pmol; n6; P0.05; Figure 4B), TFPI protein was higher
(6.01.4 versus 4.41.3 ng/mL; n6; P0.05; Figure 4C),
and tPA protein was higher (Figure 3B). Consistent with
these findings, clotting time was prolonged in the presence of
supernatant from IMA (20829 seconds) as compared to SV
(11716 seconds; n4; P0.05; Figure 4D).
Migration of VSMCs From IMA and SV
TF surface expression was slightly lower in VSMCs from
IMA as compared to SV (Figure 5A). Similarly, TF surface
activity was 1.4-fold lower in IMA (n6; PNS; Figure 5B).
Migration in response to the TF/FVIIa complex (109 mol/L)
was 3.0-fold lower in VSMCs from IMA as compared to SV
(n4; P0.01; Figure 5C). PAR-2 protein expression was
similar in both cell types (n4; PNS; data not shown). A
PAR-2 cleavage blocking antibody did not affect the response
of VSMCs to TF/VIIa (n4; PNS; data not shown).
Discussion
This study demonstrates that, among the genes of the coagula-
tion system, only TF and tPA are differentially expressed in
VSMCs from IMA versus SV. TF, the key protein for thrombus
initiation, was expressed at a lower level in IMA VSMCs,
whereas tPA, a major regulator of fibrinolysis, was expressed at
a higher level in these cells. Consistently, conditioned media
from IMA VSMCs induced a smaller reduction in clotting time
of human plasma than media from SV. Moreover, IMA VSMCs
responded to TF/FVIIa by a weaker migration than those from
SV. These data demonstrate that IMA VSMCs exhibit intrinsic
functional differences as compared to those from SV regarding
the regulation of coagulation and vascular remodeling, and,
although performed in vitro, offer an explanation for the protec-
tion of IMA from thrombosis and bypass graft disease. Although
VSMCs were isolated from patients with coronary artery dis-
ease, neither IMA nor SV exhibited any atherosclerosis; hence,
their properties reflect primary intrinsic differences and may be
present in individuals without any atherosclerosis as well.
Moreover, the properties of IMA do not seem to extend to other
arteries, because it is unique in its resistance toward atheroscle-
rosis, whereas veins in general may be similar to the SV.
As the major initiator of coagulation, TF plays an important
role in the pathogenesis of thrombosis. Increased levels of TF
antigen are detectable in atheroma of patients with acute coro-
nary syndromes16; moreover, TF plasma levels are enhanced
during and after coronary artery bypass surgery, suggesting that
TF is involved in early graft occlusion.17–19 This study demon-
strates that VSMCs from IMA express less TF than those from
SV at both the RNA and the protein level.20,21 Although the
difference in TF expression is smaller and may have less
functional consequences than that in tPA expression, the lower
TF expression in IMA VSMCs may protect this vessel from
thrombotic occlusion if an endothelial erosion or denudation
occurs, which is particularly important in the early postoperative
phase. Indeed, IMA exhibits a dual protection from thrombus
formation, as it cannot only be prepared with less endothelial
damage, but its subendothelial gene expression profile is less
thrombogenic than that of the SV, where endothelial damage
during surgical preparation is extensive.
Tissue factor activity is counterbalanced by its endogenous
inhibitor, TFPI. In human arteries, TFPI diminishes throm-
bogenicity of atherosclerotic plaques and reduces fibrin as
well as platelet deposition.22 TFPI release was higher in
VSMCs from IMA than SV; hence, the lower TF expression
in IMA is not counteracted by a parallel decrease in TFPI and
therefore would be expected to represent a true protecting
factor in IMA. Because endothelial cells are a major source of
TFPI, they may modulate the balance of TF and TFPI;
however, these cells are difficult to isolate in sufficient
numbers from human bypass vessels.
Subacute or late occlusion of coronary artery bypass grafts
occurs as a result of migration and proliferation of VSMCs
leading to neointimal growth and the accelerated formation of
atherosclerotic lesions.6 Besides activating the coagulation
cascade, TF is involved in regulating vascular remodelling.
Indeed, TF is the receptor for FVIIa and as such mediates
cellular responses like migration and proliferation of
VSMCs23–25; consistently, low TF expression induces less
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Figure 4. Modulation of clotting time of human plasma by
supernatant of vascular smooth muscle cells (VSMCs) from
internal mammary artery (IMA) and saphenous vein (SV). A,
TF protein. B, TF activity. C, TFPI protein. D, Clotting time.
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arterial remodeling in vivo. IMA VSMCs did not only exhibit
lower TF expression, but also lower migration in response to
TF, indicating that the IMA is protected from both thrombus
formation and vascular remodeling. PAR-2 has been de-
scribed to play a role in signaling the migratory response to
TF/FVIIa.24 However, VSMCs from IMA and SV exhibited
similar PAR-2 protein expression, and a PAR-2 cleavage
blocking antibody did not affect migration in response to
TF/VIIa; hence, this receptor does not seem to regulate
migration in response to TF/VIIa under our experimental
conditions. The slightly lower TF surface expression and
activity in IMA as compared to SV may only in part account
for the lower migration of IMA VSMCs; hence, additional
intrinsic differences in the regulation of migration may well
exist. This interpretation is consistent with the observation
that migration of IMA VSMCs is lower than that of SV in
response to PDGF BB as well.14 These properties may protect
the IMA from remodeling and neointima formation and
thereby promote the long-term success of IMA grafts.
Although it has been clearly demonstrated that the TF
cytoplasmic domain regulates arterial remodeling in vivo,13 it
is still a matter of discussion which signal transduction events
mediate this effect. Indeed, TF/VIIa was observed to activate
the MAP kinases extracellular signal regulated kinase (ERK)
and p38, the GTPase Rac1, and different Src family mem-
bers.25–27 The role of these mediators in regulating TF/VIIa-
induced migration of VSMCs from human bypass vessels is
not known and should be investigated in additional studies.
Antithrombotic mechanisms of vascular cells include the
expression of tPA, a fibrinolytic enzyme mediating the
conversion of plasminogen to plasmin. tPA indeed induces
such an effective thrombolysis that its recombinant forms
have several therapeutic indications.28 This study reveals that
tPA is expressed at a much higher level in VSMCs from IMA
as compared to SV. VSMC supernatant from IMA indeed
exerted a lower acceleration of clotting time than supernatant
from SV, and this effect seems to be induced by a lower
release of TF and a concomitant higher release of TFPI as
well as tPA in IMA. These observations suggest a protective
role of tPA in IMA. In line with this interpretation, adenoviral
tPA gene transfer inhibits thrombus formation and promotes
vessel patency in different models of vascular injury.29,30
Hence, the higher tPA production in IMA VSMCs may be
equally important for preventing thrombotic events and main-
taining graft patency as its lower TF expression.
PAI-1 is a SERPIN that suppresses fibrinolysis by inhib-
iting the activity of tPA31; thus, excess PAI-1 activity would
be expected to overcome the actions of tPA and increase the
risk of thrombosis. However, in this study, PAI-1 gene
expression was only slightly higher in VSMCs from IMA as
compared to SV, indicating that the antithrombotic action of
tPA in the IMA grafts is, if at all, to only a minor extent
compensated by a concomitant increase in PAI-1 expression.
There is conflicting evidence on the functional role of tPA as
a migration modulating factor. Some in vitro studies suggest that
tPA stimulates VSMC migration, whereas others indicate that
tPA induces migration only in the presence of plasminogen.
More recent in vivo research reveals that tPA plays no role or
has even a beneficial effect on neointima formation32; moreover,
in vivo knockout models indicate that urokinase-type plasmin-
ogen activator (uPA), but not tPA, stimulates neointima forma-
tion.33 No difference in expression of plasminogen or uPA was
observed between VSMCs from IMA and SV, indicating that
the effect elicited by the higher tPA production in IMA is not
modulated by a concomitant difference in the expression of these
fibrinolytic proteins. Further, fibrinolysis rather than facilitation
of migration seems to represent the relevant action of tPA in
bypass graft disease, as the IMA is resistant against both
thrombotic occlusion and neointima formation, and this inter-
pretation is consistent with in vivo studies on the role of tPA in
vascular remodeling.33 Moreover, because of intrinsic differ-
ences in the regulation of chemotaxis, VSMCs from IMA
exhibit less migration than those from SV in response to
mediators as different as PDGF BB and TF/FVIIa; hence, these
cells would be expected to exhibit a weak migration even if tPA,
despite of all the existing evidence, stimulated VSMC migration
in bypass vessels.
In conclusion, this study suggests that the IMA is protected
from thrombosis and neointima formation by an impaired TF
expression in combination with an enhanced tPA production.
Although these differences elucidate some properties of IMA,
additional studies are required to fully understand the resis-
tance of this vessel toward atherosclerosis. Nevertheless,
these observations raise the question of whether a local
genetic anticoagulant treatment should be considered in
patients with venous bypass grafts in addition to systemic
antiplatelet therapy. This question, however, remains to be
answered in appropriately designed clinical trials.
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